Search

A recent study from Northwestern University examined the social and structural determinants of health influencing screening practices for patients with Hidradenitis Suppurativa (HS), a chronic inflammatory skin condition. The research found that income and gender significantly impacted screening practices, with higher-income patients more likely to receive necessary disease screening and non-male patients having higher rates of unnecessary disease and viral screening. The study highlights the need for clearer screening guidelines and further research on the role of social determinants of health in improving patient outcomes. [Extracted from the article]

A study conducted at the University of Pisa in Italy focused on the effectiveness of wide local excision and secondary intention healing in patients with moderate to severe Hidradenitis Suppurativa (HS). The research aimed to improve quality of life and mental health outcomes in these patients, who often experience significant impacts on their well-being. The study found that this combined surgical approach led to significant improvements in quality of life and mental health, suggesting that addressing both surgical and psychological aspects can enhance patient outcomes. Future research is recommended to explore long-term benefits and develop standardized postoperative care protocols. [Extracted from the article]

A recent study conducted in Europe by University Hospital Miguel Servet focused on the impact of stigmatization on patients with Hidradenitis Suppurativa (HS), a skin condition that can significantly affect quality of life. The research found that stigmatization due to physical appearance can contribute to psychological distress, including anxiety and depression, in HS patients. The study, which included data from 135 patients across 17 European countries, highlighted the importance of comprehensive management and psychological interventions to support HS patients in managing both internal distress and external reactions. [Extracted from the article]

The document discusses a Phase 2b clinical trial, NCT06685835, evaluating the efficacy and safety of Brensocatib in adults with moderate to severe Hidradenitis Suppurativa. The study aims to compare the effects of Brensocatib with a placebo, focusing on various outcome measures related to Hidradenitis Suppurativa. The trial is not yet recruiting participants, with an enrollment target of 204 individuals and a completion date set for January 28, 2027. [Extracted from the article]

Researchers at St. Vincent's University Hospital in Dublin, Ireland, conducted a study on Hidradenitis Suppurativa (HS) and its association with cardiovascular disease (CVD) risk. The study focused on biomarkers of systemic inflammation and CVD, such as the systemic immune inflammation index (SII), neutrophil/lymphocyte (NLR), platelet/lymphocyte (PLR), and monocyte/lymphocyte ratios (MLR). The findings indicated that treatment with adalimumab resulted in a rapid and sustained reduction in systemic inflammation, which correlated with CVD risk. The research concluded that SII, NLR, and PLR may predict the response to adalimumab treatment, depending on their interaction with the number of draining fistulae. [Extracted from the article]

A recent study conducted by the Department of Obstetrics and Gynecology in Royal Oak, Michigan, focused on identifying genetic risk variants associated with Hidradenitis Suppurativa (HS) using exome sequencing data from 92,455 individuals. The research aimed to enhance the clinical diagnosis of HS by identifying potential pathogenic variants in specific genes. The study highlighted the importance of personalized approaches to HS diagnosis through large-scale sequencing, offering valuable insights for the field of skin disorders. [Extracted from the article]

Researchers at the Plastic Surgery Hospital in Beijing, China, conducted a retrospective analysis on the effectiveness of single-stage split-thickness skin grafting for treating Hurley Stage III Hidradenitis Suppurativa (HS). The study included 23 patients with a success rate of 96.2% and a low recurrence rate of 1.9%. Despite high patient satisfaction, wound scarring was the most common complication observed. The research concluded that this approach is feasible for treating Hurley Stage III HS with positive outcomes and patient satisfaction during long-term follow-up. [Extracted from the article]

A study conducted by researchers at IRCCS Humanitas Research Hospital in Milan, Italy, explored the effectiveness of anti-IL-17 and anti-IL-23 drugs in treating moderate-to-severe Hidradenitis Suppurativa (HS) in patients with concomitant psoriasis. The study found that these drugs showed promise in managing both conditions, with a significant percentage of patients achieving positive outcomes. The researchers emphasized the need for longer and larger studies to further evaluate the safety and effectiveness of these treatments for patients with HS. [Extracted from the article]

A recent report from the Institute for Cancer Research and Treatment (IRCCS) discusses the impact of hidradenitis suppurativa (HS) on the quality of life of pediatric patients. The study highlights the need for early diagnosis, education, and psychological support for both pediatric and adult patients with HS. A multidisciplinary approach involving specialists and primary care providers is recommended to improve care and manage comorbidities and psychological issues in patients with HS. The full article can be accessed for free at the Dermatology Reports website. [Extracted from the article]

The article discusses how social media platforms like TikTok are being used to raise awareness about Hidradenitis Suppurativa (HS), a chronic skin condition. The study analyzed the top 100 TikTok videos related to HS from 2020 to 2024, evaluating user engagement, content characteristics, and the quality of health information presented. While TikTok can be a valuable resource for increasing awareness about HS, content from healthcare professionals and scientific research was found to garner higher user engagement and contribute to greater awareness of the condition. [Extracted from the article]

A recent study conducted by the University of Paris Saclay has identified new genetic variants potentially associated with Hidradenitis Suppurativa (HS), a chronic skin disease characterized by painful abscesses and scarring. The research highlights the multifactorial nature of HS, involving genetic, hormonal, and environmental factors, as well as its association with systemic diseases. Through whole-exome sequencing, the study identified 91 variants in the g-secretase complex and 78 variants in other genes related to the Notch pathway, keratinization, and immune response. This comprehensive catalog of variants aims to provide valuable resources for future studies on HS. [Extracted from the article]

A recent study conducted at Attikon University Hospital in Athens, Greece, explored the association between inflammatory markers and psychometric scores in patients with Hidradenitis Suppurativa (HS), a chronic inflammatory skin disorder. The research found a significant correlation between serum inflammatory markers and quality of life, emotional well-being, and loneliness assessments in HS patients. The study highlighted the close relationship between systemic inflammatory markers, clinical severity, and psychological burden in individuals with HS, emphasizing the need for further research to validate these findings. [Extracted from the article]

A recent study conducted by the University of Naples Federico II in Italy explores the management of hidradenitis suppurativa (HS) in elderly patients. The study highlights the unique challenges faced in treating HS in this population, including its chronic inflammatory nature, diverse clinical presentation, and comorbidities. Elderly patients with HS may exhibit atypical features and frequently present with multiple comorbidities, such as obesity, diabetes, and heart disease. The study emphasizes the importance of a comprehensive approach to managing HS in elderly patients, which includes pharmacological interventions, lifestyle modifications, and surgical options when necessary. Multidisciplinary collaboration between dermatologists, geriatricians, and other specialists is crucial for tailoring treatment strategies and optimizing long-term outcomes and quality of life for this special population. [Extracted from the article]

A recent report from the University of Arizona College of Medicine discusses the prescribing patterns of antibiotics for hidradenitis suppurativa (HS) between dermatology and non-dermatology clinicians in the ambulatory setting. The study utilized the National Ambulatory Medical Care Survey (NAMCS) to identify HS patient visits from 2005 to 2016. The findings showed that dermatology clinicians were more likely to prescribe tetracyclines, while non-dermatology clinicians commonly prescribed penicillins/cephalosporins. Overall, there was no significant difference in the likelihood of prescribing antibiotic therapy between the two groups. This research provides insight into the treatment approaches for HS and highlights the need for further investigation into antibiotic stewardship. [Extracted from the article]

A pilot study conducted at Zealand University Hospital in Roskilde, Denmark, examined the association between hidradenitis suppurativa (HS), a chronic inflammatory skin disease, and female infertility. The study included 161 female participants with HS, other dermatological diseases, or no skin conditions. The researchers found no significant difference in infertility rates between the three groups, and adjusting for factors that influence fertility did not alter this result. Interestingly, the study also found that lower sexual function in the HS group did not affect their desire or ability to conceive. [Extracted from the article]

A recent study conducted at the University of North Carolina Chapel Hill has explored the use of bimekizumab as a potential treatment for Hidradenitis Suppurativa (HS), a painful and inflammatory skin condition. Bimekizumab is a monoclonal antibody that targets key mediators of inflammation and has already been approved for other conditions such as psoriasis and psoriatic arthritis. The study examines the drug's mechanism of action, pharmacokinetics, and pharmacodynamics, as well as its safety and efficacy in treating HS. Recent trial data has shown positive results, and the drug is currently pending FDA review for HS treatment. [Extracted from the article]

This document provides information about a Phase 2 clinical trial, NCT06603077, for the treatment of Hidradenitis Suppurativa (HS), a skin condition characterized by painful abscesses and inflammation. The trial is evaluating the efficacy and safety of AVTX-009 compared to a placebo in patients with moderate to severe HS. It is a randomized, double-blind, and placebo-controlled study with a maximum duration of 24 weeks for each participant. The trial aims to assess the reduction in abscess and inflammatory nodule count, as well as changes in the International HS Severity Score System and other outcome measures. The trial is currently recruiting participants in the United States, with a primary completion date for data collection set for June 30, 2026. [Extracted from the article]

A recent study conducted at the University of Illinois Urbana-Champaign examined the efficacy and safety of spironolactone in treating hidradenitis suppurativa (HS) in women of childbearing age. HS is a chronic skin disease characterized by recurrent nodules in areas with a high density of apocrine sweat glands. Spironolactone, an antiandrogen therapy, is recommended for HS, but limited data exists on its use in women of childbearing age. The study found that spironolactone may offer therapeutic benefits for HS in women of childbearing age, but patients with severe disease had reduced response rates. Further research is needed to validate these findings and determine the most suitable patient profile for spironolactone therapy for HS. [Extracted from the article]

A recent study conducted at the University of North Carolina has explored the use of upadacitinib as a monotherapy for the treatment of hidradenitis suppurativa (HS) and ulcerative colitis (UC). HS and UC are chronic inflammatory conditions that can be difficult to manage. The study found that transitioning a pediatric patient to upadacitinib monotherapy resulted in clinical improvement of both her UC and HS within three months. Although upadacitinib is not currently FDA-approved for these conditions, this case report shows promise for its use in treating these complex inflammatory disorders. [Extracted from the article]

A recent study conducted by Cardiff University in the United Kingdom aimed to estimate the prevalence of hidradenitis suppurativa (HS) in the United States. The study utilized data from four US databases and applied two algorithms to identify patients with possible or diagnosed HS. The prevalence of HS ranged from 0.06% to 0.12% based on diagnosis codes alone, but increased to 0.27% to 0.41% and 0.49% to 0.78% when algorithms were used. The study highlights the importance of employing algorithms to accurately estimate the prevalence of HS and improve diagnostic delay and treatment outcomes. [Extracted from the article]

A recent report from the University of Southern California Keck School of Medicine discusses the impact of hidradenitis suppurativa (HS), a chronic skin condition, on special populations such as children, pregnant individuals, breastfeeding mothers, and the elderly. The review highlights the challenges in diagnosing and managing HS in these populations, emphasizing the need for further research to optimize care. The report also mentions the increased risk of fetal death in pregnant women with HS and the importance of considering both maternal and fetal safety in management strategies. Overall, the study underscores the lack of primary literature on HS management in these populations and calls for more research in this area. [Extracted from the article]

A recent study conducted at Sinai Hospital in Baltimore, Maryland, examined the occurrence of squamous cell carcinoma (SCC) in patients with hidradenitis suppurativa (HS), a chronic inflammatory condition. The study found that SCC arising from HS poses a high risk for metastasis, with a 5-year survival rate of 40% to 69%. The authors recommend frequent visual examination and biopsies to identify SCC early and improve prognosis. Surgical intervention for HS should always include pathologic examination of tissue. The study included a retrospective review of 124 cases, with 73% of patients being male and the mean age at SCC diagnosis being 53 years. [Extracted from the article]

Researchers from the University Medical Center Hamburg-Eppendorf in Germany have conducted a literature review on the relationship between vitamin D levels and the severity of hidradenitis suppurativa (HS), a chronic skin disease. The review included seven studies with a total of 575 patients, all of whom were found to be vitamin D deficient. The researchers found evidence suggesting that higher serum vitamin D levels were associated with less severe HS, and there was also suggestive evidence that vitamin D supplementation could have a positive impact on the course of the disease. However, further research, particularly randomized controlled trials, is needed to better understand these correlations. [Extracted from the article]

A patent application titled "Cyclic Peptides For Inhibiting Tnf Receptor 1 Activity" has been published online. The application describes the development of cyclic peptides that selectively inhibit TNFR1, a receptor involved in the signaling of the cytokine tumor necrosis factor alpha (TNFa). These peptides have the potential to treat autoimmune and inflammatory diseases such as ulcerative colitis, Crohn's disease, rheumatoid arthritis, psoriasis, and other conditions that can be treated by blocking TNFa signaling. The invention aims to provide a more targeted and effective treatment option compared to current anti-TNFa biologics. [Extracted from the article]

Researchers at Wake Forest University School of Medicine have conducted a study on the use of biologics and small molecule targeted therapies for pediatric dermatological conditions such as alopecia areata, psoriasis, atopic dermatitis, and hidradenitis suppurativa. The study found that these therapies have significantly improved the management of these chronic skin conditions. The FDA has approved several biologics and small molecule therapies for pediatric patients, with others currently in clinical trials. These treatments have shown higher efficacy and improved safety profiles compared to traditional medications. The success of these clinical trials could lead to their inclusion in treatment guidelines, offering new avenues for effective disease management and improving pediatric health outcomes. [Extracted from the article]

A recent study conducted at University Hospital in Krakow, Poland, has found that hidradenitis suppurativa (HS), a chronic inflammatory skin condition characterized by painful nodules and abscesses, often coexists with autoimmune diseases such as thyroid disorders, irritable bowel syndrome (IBS), systemic lupus erythematosus (SLE), and psoriasis. The study, which reviewed relevant literature from 2018 to 2024, revealed significant links between HS and these autoimmune diseases, suggesting shared inflammatory mechanisms. The researchers emphasize the importance of recognizing these co-morbidities for effective HS management and call for further research to enhance understanding and treatment strategies. [Extracted from the article]

The article discusses the study from Michigan State University, which has found that alexandrite laser hair removal significantly improves hidradenitis suppurativa, with a 75 percent response rate at treated sites compared to 33.33 percent at control sites. The research demonstrated the laser's effectiveness in resolving existing lesions and preventing new ones, although the study was limited by a small sample size.

The article focuses on a review from Johns Hopkins University exploring the role of diet in managing hidradenitis suppurativa (HS). Topics include the effectiveness of various dietary interventions such as the Mediterranean diet and elimination diets, the limitations due to the lack of controlled studies, and the need for future research to establish concrete dietary guidelines for HS patients.

A recent report discusses research conducted at the University of North Carolina Chapel Hill on the treatment of Hidradenitis Suppurativa, a skin condition. The study focused on the production of three-dimensional printed scaffolds coated with rifampicin-loaded microparticles to treat the lesions associated with the condition. The results showed that the scaffolds effectively released the drugs and demonstrated antimicrobial properties against bacterial strains. The researchers concluded that these scaffolds could be a promising alternative treatment for Hidradenitis Suppurativa. The research has been peer-reviewed and more information can be obtained from the University of North Carolina Chapel Hill. [Extracted from the article]

Researchers at Johannes Gutenberg University of Mainz in Germany have conducted a study on the effectiveness and safety of LAight therapy in patients with Hidradenitis Suppurativa (HS). The study analyzed the impact of real-world treatment with LAight therapy on disease activity and burden in 3,437 patients. The results showed a significant reduction in disease severity, pain, and dermatological quality of life during the 26-week treatment period. The study concludes that LAight therapy is a valuable addition to the therapeutic options for HS, providing convincing disease control across all severity levels. [Extracted from the article]

A recent study conducted at Zealand University Hospital in Denmark has found that patients with hidradenitis suppurativa (HS), a chronic inflammatory skin disease, have an increased risk of developing cancer. The study, which analyzed data from a cohort of 13,919 Danish individuals with HS, found that these patients had a 40% higher risk of developing cancer compared to the general population. The increased risks were observed for cancers of the respiratory system, oral cavity and pharynx, digestive organs and peritoneum, urinary tract, and lymphatic tissues. The researchers suggest that there is a need for health monitoring, lifestyle interventions, and cancer screening for individuals with HS. [Extracted from the article]

A case report from the Hospital of Chengdu University of Traditional Chinese Medicine in China discusses a rare case of widespread soft tissue infection and multiple abscesses caused by Lawsonella clevelandensis in a patient with hidradenitis suppurativa (HS). The patient experienced severe pain, pus discharge, and irreversible tissue destruction. The infection was difficult to diagnose and cultivate, but gene analysis confirmed the presence of L. clevelandensis. The patient eventually recovered after abscess drainage and antibiotic therapy. The report suggests that next-generation sequencing (NGS) can be a valuable diagnostic tool for individuals with recurrent skin infections and multiple abscesses when conventional methods are inconclusive. [Extracted from the article]

A recent study conducted by Harvard Medical School has compared the transcriptomic data of three inflammatory skin conditions: acne vulgaris, rosacea, and hidradenitis suppurativa. The study identified zinc-binding proteins that were consistently upregulated in all three diseases, suggesting a potential link between zinc deficiency and inflammation. The researchers proposed high-dose dietary zinc as a promising therapeutic approach and confirmed its effectiveness in an acne mouse model. This research provides valuable insights for refined diagnostics, effective management, and targeted therapeutic interventions for these skin conditions. [Extracted from the article]

A recent study conducted at Kaohsiung Chang Gung Memorial Hospital in Taiwan explored the use of adalimumab, a biologic agent, combined with surgery in the management of moderate to severe Hidradenitis Suppurativa (HS). The study analyzed the medical charts of 102 clinically diagnosed HS patients and found that the combination of adalimumab and surgery resulted in a 68.4% improvement rate. The study also noted that smoking and obesity were prevalent among the patients. While the study had limitations, it revealed the benefits of integrating adalimumab with suitable surgical procedures in managing moderate to severe HS in real-world scenarios. [Extracted from the article]

The article from Pennsylvania State University (Penn State) College of Medicine details new findings in hidradenitis suppurativa (HS), a complex inflammatory skin condition. Topics include the need for standardized reporting of clinical and demographic data in HS research, the higher incidence of HS in specific populations such as females and Black individuals, and the impact of data harmonization on improving understanding and patient care for HS.

The article focuses on the efficacy of upadacitinib in treating psoriasiform eczema and related immune-mediated conditions. Topics include the effectiveness of upadacitinib on psoriasiform eczema and associated comorbidities like alopecia areata and vitiligo, the varying outcomes for different conditions, and the need for further research to confirm its broader efficacy.

A recent study conducted by researchers at Rockefeller University in New York City has shed light on the potential role of eosinophils in the inflammatory skin disease known as Hidradenitis Suppurativa (HS). HS is characterized by painful nodules, abscesses, and purulent secretions in intertriginous regions, often accompanied by intense pruritus. The study found that HS patients exhibited decreased mature eosinophils and increased numbers of immature eosinophils in their blood, along with a significant increase in dermal eosinophilic infiltrates. These findings suggest that eosinophils may participate in the pathogenesis of HS and could potentially be targeted for therapeutic interventions. Further research is needed to explore the response of eosinophils to current HS treatments. [Extracted from the article]

Researchers at the University Hospital Heraklion in Crete, Greece, have conducted a study on antibiotic resistance in patients with hidradenitis suppurativa (HS), a chronic skin condition. The study found that 79.86% of skin lesions tested positive for bacteria, with Gram-positive isolates accounting for 73% and Gram-negative isolates comprising 27%. The antibiogram profiles revealed high resistance rates to various antibiotics, including levofloxacin, penicillin, and tigecycline. The researchers concluded that patients with HS display significant resistance to bacterial proliferation, and revised therapeutic guidelines should consider the latest insights into antibiotic resistance. [Extracted from the article]

This document provides information about a clinical trial for the drug Lutikizumab, which aims to assess its efficacy in treating Hidradenitis Suppurativa (HS) and Atopic Dermatitis (AD). The trial is divided into two sub-studies, one for HS and one for AD, and will enroll approximately 60 participants at two sites in the US. Participants will receive subcutaneous injections of Lutikizumab for a specified period, followed by a follow-up period. The trial is open to individuals of all genders between the ages of 18 and 75 and is regulated by the U.S. FDA. [Extracted from the article]

Novartis Pharmaceuticals is conducting two studies to assess the real-world effectiveness of secukinumab in treating Hidradenitis Suppurativa (HS). The first study, NCT06517732, is a clinical trial taking place in the Russian Federation. It aims to collect data on the proportion of patients achieving a 55% reduction in disease severity, as well as other treatment-related factors. The second study, ANIMA-R, is an observational study that will collect data from patients receiving routine secukinumab treatment as prescribed by their attending physician. Both studies are expected to be completed by June 2026 and aim to provide valuable insights into the effectiveness of secukinumab for HS treatment. [Extracted from the article]